Organism list not requested in this search

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL (FLAVONOID)

ACETANILIDE 4-HYDROXYLASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 31.4 MICROMOLS/ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP1A2.

ADIPOCYTE CONVERSION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30201 *

AFLATOXIN B1 METABOLISM INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED NOT STATED ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.

ALKALINE PHOSPHATASE STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0N MOL/INACTIVE * L04448 * VS.HUMAN ENDOMETRIAL CELLS, ISHIKAWA VAR I.

ALKALINE PHOSPHATASE STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * IN HUMAN FETAL OSTEOBLAST CELL LINE HFOB/ER

ANTIANGIOGENIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30198 * VS.KS-IMM CELLS.

ANTIBACTERIAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * AGAR PLATE * MIC 12.5 MCG/ML * ACTIVE * STREPTOCOCCUS SPECIES * L26307 *

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL (FLAVONOID)

ANTICOCCIDIAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * EIMARIA MAXIMA * SEE ARTICLE FOR OTHER TEST RESULTS. * L30197 *

ANTICOCCIDIAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VIVO * IN RATION * CHICKEN * CONC USED 20.0 PPM/ACTIVE * EIMERIA TENELLA * L30197 *

ANTICOCCIDIAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VIVO * IN RATION * CHICKEN * CONC USED 20.0 PPM/ACTIVE * EIMARIA MAXIMA * L30197 *

ANTICOCCIDIAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VIVO * IN RATION * CHICKEN * CONC USED 20.0 PPM/ACTIVE * EIMERIA ACERVULINA * L30197 *

ANTICYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * HEPATOCYTES * L15429 * VS.TBH-INDUCED CYTOTOXICITY.

ANTIHYPERLIPEMIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VIVO * IN RATION * MOUSE * DOSE 1.0 % OF DIET/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30228 * VS. PLASMA AND HEPATIC TRIGLYCERIDE LEVELS. 31 DAYS DOSING

ANTIINVASIVE ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30199 * VS. MCF-7 AND T47-D BREAST CANCER CELL LINES.

ANTIMALARIAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 1.0 MCG/ML * ACTIVE * PLASMODIUM FALCIPARUM * L25890 *

ANTIMALARIAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 8.2 MICROMOLS/ACTIVE * PLASMODIUM FALCIPARUM * SEE ARTICLE FOR OTHER TEST RESULTS. * L30185 *

XANTHOHUMOL (FLAVONOID)

ANTIMUTAGENIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 2.0 MICROMOLS/ACTIVE * L27371 * 48% INHIBITION INDUCED B IQ.

ANTIMUTAGENIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 0.1 MILLIMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30335 * VS. SEVERAL MUTAGENIC CHALLENGES IN HEP-G-2-CELLS.

ANTIMUTAGENIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * AGAR PLATE * CONCENTRATION NOT GIVEN NOT STATED ACTIVE * SALMONELLA TYPHIMURIUM TA98 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30636 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.TBARS FORMATION IN LDL.

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 24% INHIBITION.

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS. DPPH ASSAY

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.2 MICROMOLS/ACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.2 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 30.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30335 * VS. DPPH ASSAY.

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 3.47 MICROMOLS/ACTIVE * CA-MAMMARY-MCF-7 * L03979 *

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * HUMAN COLON CANCER CELL LINE HT29 * L03979 *

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 0.52 MICROMOLS/ACTIVE * CA-HUMAN-OVARIAN A2780 * L03979 *

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29422 * USING MTT ASSAY IN BENIGN PROSTATIC HYPERPLASIA AND ANDROGEN INDEPENDENT PROSTATE CANCER CELL LINES

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 13.2 MICROMOLS/ACTIVE * CA-PC3(PROSTATE) * L30466 *

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 12.3 MICROMOLS/CA-HUMAN-PROSTATE-DU 145 * L30466 *

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL (FLAVONOID)

ANTIVIRAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 1.7 MCG/ML * ACTIVE * VIRUS-BOVINE VIRAL DIARRHEA(BVDV) * L25902 *

ANTIVIRAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 2.5 MCG/ML * ACTIVE * VIRUS-CYTOMEGALOVIRUS * L25902 *

ANTIVIRAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 2.7 MCG/ML * ACTIVE * VIRUS-HERPES SIMPLEX 1 * L25902 *

ANTIVIRAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 1.5 MCG/ML * ACTIVE * VIRUS-HERPES SIMPLEX 2 * L25902 *

ANTIVIRAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * VIRUS-RHINOVIRUS * L25902 *

ANTIVIRAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 0.82 MCG/ML * ACTIVE * VIRUS-HIV-1 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30188 *

APOPTOSIS INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 1.0 MCG/ML * ACTIVE * LEUK-HL60 * DATA INCOMPLETE - DERIVED FROM AN ABSTRACT. * L19788 *

APOPTOSIS INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 2.6 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L26906 * VS.40-16 HUMAN COLON CANCER CELLS.

APOPTOSIS INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29422 * USING ANNEXIN V ASSAY IN HUMAN BENIGN PROSTATIC HYPERPLASIA (BPH-1) EPITHELIAL AND ANDROGEN INDEPENDENT PROSTATE CANCER CELL LINES

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL (FLAVONOID)

APOPTOSIS INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 75.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30201 * VS.3T3-L-1 FIBROBLASTS.

AROMATASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 3.2 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30162 * VS. BREAST CANCER CELLS SK-BR-3

AROMATASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 20.3 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30195 * VS.JAR CELLS.

BINDING EFFECT

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30191 * BINDING TO CYTOSOLIC PROTEINS IN CACO-2 CELLS MAY CONTRIBUTE TO THE POOR BIOAVAILABILITY OF XANTHOHUMOL.

CARCINOGENESIS INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30218 * USING AN ONLINE LC/MS SCREENING ASSAY BASED ON THE MASS SPECTROMETRIC IDENTIFICATION OF COMPOUNDS THAT ALKYLATE THE CYTOPLASMIC ACTIN-BINDING KEAP1 PROTEIN, LEADING TO THE UPREGULATION OF ANTIOXIDANT RESPONSE ELEMENT-MEDIATED INDUCTION OF PHASE II DETOXIFYING AND ANTIOXIDATIVE STRESS ENZYME NRF2

CARCINOGENESIS INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * MOUSE * IC50 0.02 MICROMOLS/ACTIVE * VS.FORMALIN-INDUCED PEDAL EDEMA. * L30258 * VS. INCIDENCE OF DMBA-INDUCED LESIONS IN MOUSE MAMMARY ORGAN CULTURE

CARCINOGENESIS INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * MOUSE * IC50 0.02 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * VS. INCIDENCE OF DMBA-INDUCED LESIONS IN MOUSE MAMMARY ORGAN CULTURE

CASPASE-3 STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/INACTIVE * CA-HUMAN-PROSTATE PC-3 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 *

CELL PROLIFERATION STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * CA-HUMAN-BREAST-MCF-7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 *

XANTHOHUMOL (FLAVONOID)

CHLORZOXAZONE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP2E1.

COLONY FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 30.0 MCG/ML * ACTIVE * CELLS-HAMSTER-CHINESE-V79 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * SEVEN DAY INCUBATION

CYSTEINE PROTEASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED NOT STATED ACTIVE * DATA INCOMPLETE - DERIVED FROM AN ABSTRACT. * L19788 *

CYTOCHROME P450 STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.2 MICROMOLS/ACTIVE * L27371 * VS.HUMAN CYP-1-A-2.

CYTOPROTECTIVE ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10 MCG/ML * ACTIVE * CA-HEPATOCARCINOMA-G2 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30636 * VS. 2-AMINO-3-METHYLIMIDAZO[4,5-F] QUINOLINE INDUCED DNA DAMAGE

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * CA-MAMMARY-MCF-7 * L03979 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * HUMAN COLON CANCER CELL LINE HT29 * L03979 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * CA-HUMAN-OVARIAN A2780 * L03979 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 24.4 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L26907 * VS.B-CHRONIC LYMPHOCYTIC LEUKEMIA CELLS.

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 30.7 MICROMOLS/EQUIVOCAL * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL (FLAVONOID)

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/ACTIVE * HUMAN PROSTATE CANCER CELL LINE DU-145 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/ACTIVE * CA-HUMAN-PROSTATE PC-3 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10 MCG/ML * EQUIVOCAL * CA-HEPATOCARCINOMA-G2 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30636 *

DIACYLGLYCEROL ACYLTRANSFERASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * RAT * IC50 50.3 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * H20962 *

DIACYLGLYCEROL ACYLTRANSFERASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 21.2 MICROMOLS/ACTIVE * CELLS-RAJI * H20962 *

DNA FRAGMENTATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MCG/ML * WEAK ACTIVITY * LEUK-HL60 * DATA INCOMPLETE - DERIVED FROM AN ABSTRACT. * L19788 *

DNA POLYMERASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 23.0 MICROMOLS/ACTIVE * HUMAN BREAST CANCER CELL LINE MDA -MB-435 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 *

XANTHOHUMOL (FLAVONOID)

DNA SYNTHESIS INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 0.5 MICROMOLS/ACTIVE * CA-MAMMARY-MCF-7 * L03979 *

DRUG METABOLIZING ENZYME INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 0.022 MICROMOLS/ACTIVE * HEPATOMA-H4IIEC3/G * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * VS INHIBITION OF CYP1A, A PHASE I (CONJUGATING) ENZYME

ESTROGENIC EFFECT

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED NOT STATED INACTIVE * L14681 * IN ISHIKAWA CELLS.

ESTROGENIC EFFECT

PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27370 * VS. ER-ALPHA AND ER-BETA.

ESTROGENIC EFFECT

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MCG/ML * ACTIVE * OSTEOSARCOMA-U-2 OS * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * VS. REGULATION OF ESTROGEN-INDUCIBLE GENE EXPRESSION

ETHOXYRESORUFIN-O-DEETHYLASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L10219 * VS.HUMAN P450 CYP1B1 AND HUMAN P450 CYP1A1.

FERTILITY PROMOTION EFFECT

PHARMACOLOGY OF COMPOUND - IN VIVO * INTRAGASTRIC * RAT * DOSE 100.0 MG/KG * INACTIVE * L26909 *

GABA RECEPTOR BINDING STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 75.0 NANOMOLS/ACTIVE * NEURON * L30576 * IN HIPPOCAMPAL N EURONS.

GABA RECEPTOR MODULATORY EFFECT

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 75.0 NANOMOLS/STRONG ACTIVITY * CELLS-HIPPOCAMPAL NEURON * SEE ARTICLE FOR OTHER TEST RESULTS. * L30230 *

XANTHOHUMOL (FLAVONOID)

GENOTOXICITY INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.001 MICROMOLS/ACTIVE * LIVER * L30577 * VS-IQ AND BAP-INDUCED DNA DAMAGE.

HYPERPROTHROMBINEMIA EFFECT

PHARMACOLOGY OF COMPOUND - IN VIVO * SC * MOUSE * DOSE 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30198 *

IODIDE UPTAKE STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27089 * IN RAT THYROID-DERIVED FRTL-5 CELLS

LDL OXIDATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.CONJUGATED DIENE FORMATION IN LDL.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 6.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.

METABOLISM OF

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED ACTIVE * L08929 * METABOLISM TO ISOXANTHOHUMOL.

METABOLISM OF

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED VAR ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L26905 * THE STUDY SUGGESTED A PROMINENT ROLE FOR THE GLUCURONIDATION AND SULFATION OF XN IN THE LIVER AS WELL AS IN THE GASTROINTESTINAL TRACT.

XANTHOHUMOL (FLAVONOID)

METABOLISM OF

PHARMACOLOGY OF COMPOUND - IN VIVO * INTRAGASTRIC * RAT * DOSE 1000 MG/KG * ACTIVE * L27032 * 16 METABOLITES AND 6 PREVIOUSLY KNOWN METABOLITES WERE ISLOATED.

METABOLISM OF

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27365 * METABOLIZED TO TWO MAJOR GLUCURONIDES BY RAT AND HUMAN MICROSOMES

METABOLISM OF

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27367 * CONVERSION TO CHALCONE DERIVATIVES BY RAT LIVER MICROSOMES.

METABOLISM OF

PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29205 * METABOLIZED TO ISOXANTHOHUMOL.

METABOLISM STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * CA-HEPATOCARCINOMA-G2 * L30228 * VS. ACTIVATION OF FARNESOID RECEPTOR X AND MODULATION OF GENES INVOLVED IN LIPID AND GLUCOSE METABOLISM

MISCELLANEOUS EFFECTS

PHARMACOLOGY OF COMPOUND - IN VIVO * INTRAGASTRIC * RAT * DOSE 100.0 MG/KG * INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L26908 * VS.COMPOSITION OF INTESTINAL MICROBIOTA.

NIFEDIPINE OXIDASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.

NITRIC OXIDE RELEASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MCG/ML * ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H31111 * VS.LPS/INF-GAMMA INDUCED NO.

NITRIC OXIDE SYNTHESIS INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 8.3 MICROMOLS/ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H32723 *

NUCLEAR FACTOR KAPPA-BETA INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29422 * IN HUMAN BENIGN PROSTATIC HYPERPLASIA EPITHELIAL (BPH-1) CELLS

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL (FLAVONOID)

PHASE II ENZYME INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 1.7 MICROMOLS/ACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * CONCENTRATION REQUIRED TO DOUBLE QUINONE REDUCTASE ACTIVITY

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CD50 2.1 MICROMOLS/ACTIVE * L27369 *

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 1.7 MICROMOLS/ACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 2.0 MCG/ML * ACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30218 * ASSAY USED TO DETERMINE THE CONCENTRATION REQUIRED TO DOUBLE QUINONE REDUCTASE ACTIVITY.

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 1.7 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

RADICAL SCAVENGING EFFECT

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 1.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 *

REVERSE TRANSCRIPTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 1.28 MCG/ML * ACTIVE * VIRUS-HIV-1 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30188 *

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL (FLAVONOID)

TOXIC EFFECT(GENERAL)

PHARMACOLOGY OF COMPOUND - IN VIVO * INTRAGASTRIC * RAT * DOSE 1000 MG/KG * ACTIVE * L26909 *

XANTHOHUMOL B (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-C-2-ARE-C-8 CELLS

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

DIACYLGLYCEROL ACYLTRANSFERASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * RAT * IC50 194.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * H20962 *

DIACYLGLYCEROL ACYLTRANSFERASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 33.8 MICROMOLS/ACTIVE * CELLS-RAJI * H20962 *

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL B (FLAVONOID)

NITRIC OXIDE RELEASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 1.0 MCG/ML * ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H31111 * VS.LPS/INF-GAMMA INDUCED NO.

NITRIC OXIDE SYNTHESIS INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 5.6 MICROMOLS/ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H32723 *

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 4.5 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 4.5 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

XANTHOHUMOL B,DEMETHYL: (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 *

XANTHOHUMOL B,DEMETHYL: (FLAVONOID)

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 2.7 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

XANTHOHUMOL C (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 4.8 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL C (FLAVONOID)

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 4.8 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

XANTHOHUMOL D (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

CARCINOGENESIS INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30218 * USING AN ONLINE LC/MS SCREENING ASSAY BASED ON THE MASS SPECTROMETRIC IDENTIFICATION OF COMPOUNDS THAT ALKYLATE THE CYTOPLASMIC ACTIN-BINDING KEAP1 PROTEIN, LEADING TO THE UPREGULATION OF ANTIOXIDANT RESPONSE ELEMENT-MEDIATED INDUCTION OF PHASE II DETOXIFYING AND ANTIOXIDATIVE STRESS ENZYME NRF2

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

NITRIC OXIDE RELEASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MCG/ML * ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H31111 * VS.LPS/INF-GAMMA INDUCED NO.

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL D (FLAVONOID)

NITRIC OXIDE SYNTHESIS INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 9.4 MICROMOLS/ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H32723 *

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 7.8 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 7.4 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

XANTHOHUMOL G (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

XANTHOHUMOL G (FLAVONOID)

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 4.5 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

XANTHOHUMOL H (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 7.1 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 7.1 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

BIOLOGICAL ACTIVITIES ISOLATED FOR XANTHOHUMOL%

XANTHOHUMOL I (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED >30.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

XANTHOHUMOL J,DEMETHYL: (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY

XANTHOHUMOL J,DEMETHYL: (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 7.8 MICROMOLS/ACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 7.8 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

XANTHOHUMOL K,1''-2''-DIHYDROXY (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS

XANTHOHUMOL K,1''-2''-DIHYDROXY (FLAVONOID)

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 2.5 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

XANTHOHUMOL,2''-3''-DIHYDRO: (FLAVONOID)

ANTIMALARIAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 12.9 MICROMOLS/ACTIVE * PLASMODIUM FALCIPARUM * SEE ARTICLE FOR OTHER TEST RESULTS. * L30185 *

XANTHOHUMOL,4'-O-5'-C-DIPRENYL: (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 88% INHIBITION.

XANTHOHUMOL,4'-O-5'-DIPRENYL: (FLAVONOID)

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.

XANTHOHUMOL,4'-O-5'-DIPRENYL; (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 *

XANTHOHUMOL,4'-O-METHYL: (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.TBARS FORMATION IN LDL.

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 51% INHIBITION.

LDL OXIDATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * L10217 * VS.CONJUGATED DIENE FORMATION IN LDL.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.

XANTHOHUMOL,4'-O-METHYL; (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 *

XANTHOHUMOL,5'-PRENYL: (FLAVONOID)

ACETANILIDE 4-HYDROXYLASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP1A2.

XANTHOHUMOL,5'-PRENYL: (FLAVONOID)

ANTICYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * HEPATOCYTES * L15429 * VS.TBH -INDUCED CYTOTOXICITY.

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.TBARS FORMATION IN LDL.

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 31% INHIBITION.

CHLORZOXAZONE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP2E1.

ETHOXYRESORUFIN-O-DEETHYLASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * L10219 * VS.HUMAN P450 CYP1B1 AND HUMAN P450 CYP1A1.

LDL OXIDATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/INACTIVE * L10217 * VS.CONJUGATED DIENE FORMATION IN LDL.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.

NIFEDIPINE OXIDASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.

XANTHOHUMOL,5'-PRENYL; (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 *

XANTHOHUMOL,5''-TRANS-HYDROXY: (FLAVONOID)

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.2 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 10.2 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

XANTHOHUMOL,6-8-DIPRENYL: (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 *

XANTHOHUMOL,6-8-DIPRENYL: (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * THE CORRECT IDENTIFICATION OF THIS PLANT IS HIGHLY QUESTIONABLE. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.1 MICROMOLS/WEAK ACTIVITY * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

XANTHOHUMOL,6'-DEMETHYL: (FLAVONOID)

ANTIMALARIAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 42.4 MICROMOLS/WEAK ACTIVITY * PLASMODIUM FALCIPARUM * SEE ARTICLE FOR OTHER TEST RESULTS. * L30185 *

XANTHOHUMOL,DEMETHYL: (FLAVONOID)

ANTICYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/INACTIVE * HEPATOCYTES * L15429 * VS.TBH-INDUCED CYTOTOXICITY.

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L30184 * VS.BJAB CELLS.

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 49.9 MICROMOLS/ACTIVE * CA-PC3(PROSTATE) * L30466 *

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 53.8 MICROMOLS/ACTIVE * CA-HUMAN-PROSTATE-DU 145 * L30466 *

XANTHOHUMOL,DEMETHYL: (FLAVONOID)

APOPTOSIS INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30184 * VS.BJAB CELLS.

APOPTOSIS INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 50.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30184 * VS.BJAB CELLS.

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30184 *

ESTROGENIC EFFECT

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * L14681 * IN ISHIKAWA CELLS.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CD50 7.5 MICROMOLS/ACTIVE * L27369 *

XANTHOHUMOL,DEMETHYL; (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 *

XANTHOHUMOL,DIHYDRO: (FLAVONOID)

NITRIC OXIDE SYNTHESIS INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 23.0 MICROMOLS/ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H32723 *

XANTHOHUMOL,DIHYDROXY: (FLAVONOID)

NITRIC OXIDE RELEASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MCG/ML * ACTIVE * MACROPHAGE CELL LINE RAW 264.7 * H31111 * VS.LPS/INF-GAMMA INDUCED NO.

XANTHOHUMOL,DIPRENYL: (FLAVONOID)

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 5.1 MICROMOLS/ACTIVE * L29296 *

XANTHOHUMOL,ISO: (FLAVANONE)

ACETANILIDE 4-HYDROXYLASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 4.5 MICROMOLS/ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP1A2.

ADIPOCYTE CONVERSION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30201 *

AFLATOXIN B1 METABOLISM INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.

ALKALINE PHOSPHATASE STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * IN HUMAN FETAL OSTEOBLAST CELL LINE HFOB/ER

ANTIMUTAGENIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 2.0 MICROMOLS/NOT POSSIBLE TO INTERPRET RESULTS * L27371 * 84% INHIBITION INDUCED BY IQ.

XANTHOHUMOL,ISO: (FLAVANONE)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * L10217 * VS.TBARS FORMATION IN LDL.

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 100% INHIBITION.

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.DPPH ASSAY

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * VS.INHIBITION OF 1-1-DIPHENYL-2-PICRYLHYDRAZYL RADICAL FORMATION. * L30193 *

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 200.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 4.69 MICROMOLS/ACTIVE * CA-MAMMARY-MCF-7 * L03979 *

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * HUMAN COLON CANCER CELL LINE HT29 * L03979 *

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED WEAK ACTIVITY * CA-HUMAN-OVARIAN A2780 * L03979 *

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 45.2 MICROMOLS/ACTIVE * CA-PC3(PROSTATE) * L30466 *

ANTIPROLIFERATION ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 47.4 MICROMOLS/ACTIVE * CA-HUMAN-PROSTATE-DU 145 * L30466 *

XANTHOHUMOL,ISO: (FLAVANONE)

ANTIVIRAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * VIRUS-BOVINE VIRAL DIARRHEA (BVDV) * L25902 *

ANTIVIRAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 12.0 MCG/ML * ACTIVE * VIRUS-CYTOMEGALOVIRUS * L25902 *

ANTIVIRAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED NOT STATED INACTIVE * VIRUS-HERPES SIMPLEX 1 * L25902 *

ANTIVIRAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 17.0 MG/ML * ACTIVE * VIRUS-HERPES SIMPLEX 2 * L25902 *

ANTIVIRAL ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 6.6 MCG/ML * ACTIVE * VIRUS-RHINOVIRUS * L25902 *

APOPTOSIS INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION NOT GIVEN NOT STATED MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L30201 * VS.3T3-L-1 FIBROBLASTS.

AROMATASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 25.4 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30162 * VS. BREAST CANCER CELLS SK-BR-3

XANTHOHUMOL,ISO: (FLAVANONE)

AROMATASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 139.7 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L30195 * VS.JAR CELLS.

CARCINOGENESIS INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * NOT STATED INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30218 * USING AN ONLINE LC/MS SCREENING ASSAY BASED ON THE MASS SPECTROMETRIC IDENTIFICATION OF COMPOUNDS THAT ALKYLATE THE CYTOPLASMIC ACTIN-BINDING KEAP1 PROTEIN, LEADING TO THE UPREGULATION OF ANTIOXIDANT RESPONSE ELEMENT-MEDIATED INDUCTION OF PHASE II DETOXIFYING AND ANTIOXIDATIVE STRESS ENZYME NRF2

CASPASE-3 STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/INACTIVE * CA-HUMAN-PROSTATE PC-3 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 *

CELL PROLIFERATION STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONCENTRATION VARIABLE NOT STATED ACTIVE * CA-HUMAN-BREAST-MCF-7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 *

CHLORZOXAZONE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP2E1.

COLONY FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 30.0 MCG/ML * ACTIVE * CELLS-HAMSTER-CHINESE-V79 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * SEVEN DAY INCUBATION

CYCLIC AMP PHOSPHODIESTERASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * IC50 >5.0 MILLIMOLS/INACTIVE * M12709 *

CYTOCHROME P450 INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MICROMOLS/ACTIVE * MICROSOMES-HUMAN-LIVER * SEE ARTICLE FOR OTHER TEST RESULTS. * L30215 * ONLINE LC/MS ASSAY USED TO DETERMINE KINETICS OF PRENYL OXIDATION OF XANTHOHUMOL IN A VARIETY OF P450 ENZYME ISOTYPES.

XANTHOHUMOL,ISO: (FLAVANONE)

CYTOCHROME P450 STIMULATION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L27371 * VS.HUMAN CYP-1-A-2.

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * CA-MAMMARY-MCF-7 * L03979 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * HUMAN COLON CANCER CELL LINE HT29 * L03979 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 100.0 MICROMOLS/WEAK ACTIVITY * CA-HUMAN-OVARIAN A2780 * L03979 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 30.7 MICROMOLS/WEAK ACTIVITY * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 * VS.HEP-G-2-ARE-C-8 CELLS

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 >20.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/ACTIVE * HUMAN PROSTATE CANCER CELL LINE DU-145 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 *

CYTOTOXIC ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 200 MICROMOLS/ACTIVE * CA-HUMAN-PROSTATE PC-3 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30253 *

XANTHOHUMOL,ISO: (FLAVONOID)

DNA POLYMERASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * IC50 100.0 MICROMOLS/INACTIVE * HUMAN BREAST CANCER CELL LINE MDA-MB-435 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 *

XANTHOHUMOL,ISO: (FLAVANONE)

DNA SYNTHESIS INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 0.5 MICROMOLS/ACTIVE * CA-MAMMARY-MCF-7 * L03979 *

XANTHOHUMOL,ISO: (FLAVONOID)

DRUG METABOLIZING ENZYME INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 0.3 MICROMOLS/ACTIVE * HEPATOMA-H4IIEC3/G * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * VS INHIBITION OF CYP1A, A PHASE I (CONJUGATING) ENZYME

XANTHOHUMOL,ISO: (FLAVANONE)

ESTROGENIC EFFECT

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 10.0 MCG/ML * ACTIVE * OSTEOSARCOMA-U-2 OS * SEE ARTICLE FOR OTHER TEST RESULTS. * L30229 * VS. REGULATION OF ESTROGEN-INDUCIBLE GENE EXPRESSION

ETHOXYRESORUFIN-O-DEETHYLASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L10219 * VS.HUMAN P450 CYP1B1 AND HUMAN P450 CYP1A1.

LDL OXIDATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/INACTIVE * L10217 * VS.CONJUGATED DIENE FORMATION IN LDL.

METABOLISM OF

PHARMACOLOGY OF COMPOUND - IN HUMANS * ORAL * HUMAN ADULT * DOSE 5.59 MG/DAY * ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * E02273 * DAILY DOSING FOR FOUR DAYS (3 WOMEN) WITH CONVERSION TO 8-PRENYL NARINGENIN. THIS OCCURS IN THE DISTAL COLON.

METABOLISM OF

PHARMACOLOGY OF COMPOUND - IN VITRO * AGAR PLATE * CONCENTRATION NOT GIVEN NOT STATED SEE ARTICLE FOR OTHER TEST RESULTS. * E02286 * STANDARDIZED EXTRACTS WERE INCUBATED WITH FECAL SLURRY FROM FEMALE HUMAN SUBJECTS (N=100) TO DETERMINE VARIATION IN METABOLIC PATTERNS AND BACTERIAL CONVERSION RATES.

METABOLISM OF

PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED ACTIVE * L28323 * EUBACTERIUM LIMOSUM FROM FECAL FLORA METABOLIZED ISOXANTHOHUMOL TO 8-PRENARINGENIN IN 90% YIELD.

XANTHOHUMOL,ISO: (FLAVANONE)

METABOLISM OF

PHARMACOLOGY OF COMPOUND - IN VITRO * CONCENTRATION VARIABLE NOT STATED ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29205 * METABOLIZED TO HYDROXYLATION OF THE PRENYL GROUP.

METABOLISM OF

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/. * MICROSOMES-HUMAN-LIVER * L30574 * METABOLISM BY CYTOCHROME P450 ENZYME CYP1A2.

NIFEDIPINE OXIDASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.

XANTHOHUMOL,ISO: (FLAVONOID)

PHASE II ENZYME INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 6.5 MICROMOLS/ACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 * CONCENTRATION REQUIRED TO DOUBLE QUINONE REDUCTASE ACTIVITY

XANTHOHUMOL,ISO: (FLAVANONE)

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED >50.0 MICROMOLS/INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30193 *

QUINONE REDUCTASE INDUCTION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED <50.0 MCG/ML * INACTIVE * HEPATOMA-HEPA-1C1C7 * SEE ARTICLE FOR OTHER TEST RESULTS. * L30218 * ASSAY USED TO DETERMINE THE CONCENTRATION REQUIRED TO DOUBLE QUINONE REDUCTASE ACTIVITY.

QUINONE REDUCTASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * ED50 >50.0 MICROMOLS/INACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L29296 *

XANTHOHUMOL,ISO: (FLAVONOID)

RADICAL SCAVENGING EFFECT

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 1.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L30258 *

XANTHOHUMOL,TETRAHYDRO: (FLAVONOID)

ACETANILIDE 4-HYDROXYLASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP1A2.

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.TBARS FORMATION IN LDL.

CHLORZOXAZONE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN CYP2E1.

ETHOXYRESORUFIN-O-DEETHYLASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/ACTIVE * L10219 * VS.HUMAN P450 CYP1B1 AND HUMAN P450 CYP1A1.

LDL OXIDATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * L10217 * VS.CONJUGATED DIENE FORMATION IN LDL.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FERROUS SULFATE INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 25.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.FE3+-ADP/NADPH INDUCED LIPID PEROXIDATION.

LIPID PEROXIDE FORMATION INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 5.0 MICROMOLS/ACTIVE * MICROSOMES-RAT-LIVER * L15429 * VS.TERT-BUTYL HYDROPEROXIDE INDUCED LIPID PEROXIDATION.

NIFEDIPINE OXIDASE INHIBITION

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 10.0 MICROMOLS/INACTIVE * L10219 * VS.CDNA-EXPRESSED HUMAN P450 CYP1A2-METABOLISM OF AFB1.

XANTHOHUMOL,TETRAHYDROXY: (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CONC USED 0.1 MG/ML * ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27368 * VS.LIPID PEROXIDATION INDUCED BY SIN-1 IN LDL. 92% INHIBITION.

XANTHOHUMOL,TETRAHYDROXY; (FLAVONOID)

ANTIOXIDANT ACTIVITY

PHARMACOLOGY OF COMPOUND - IN VITRO * CELL CULTURE * CONC USED 5.0 MICROMOLS/ACTIVE * SEE ARTICLE FOR OTHER TEST RESULTS. * L27366 *

LITERATURE CITED

E02273 THE PRENYLFLAVONOID ISOXANTHOHUMOL FROM HOPS (HUMULUS IUPULUS L.) IS ACTIVATED INTO THE POTENT PHYTOESTROGEN 8-PRENYLNARINGENIN IN VITRO AND IN THE HUMAN INTESTINE

POSSEMIERS,S: BOLCA,S: GROOTAERT,C: HEYERICK,A: DECROSS,K: DHOOGE,W: DE KEUKELEIRE,D: RABOT,S: VERSTRAETE,W: VAN DE WIELE,T:

J NUTR (2006) 136 pp. 1862-1867 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

GHENT UNIVERSITY LABO MICROBIAL ECOLOGY TECHNOLOGY FACULTY BIOSCIENCE ENGINEERING GENT B-9000 BELGIUM

E02286 METABOLISM OF ISOFLAVONES, LIGNANS AND PRENYLFLAVONOIDS BY INTESTINAL BACTERIA: PRODUCER PHENOTYPING AND RELATION WITH INTESTINAL COMMUNITY

POSSEMIERS,S: EECKHAUDT,E: DEPYPERE,H: VERSTRAETE,W

FEMS MICROBIAL ECOL (2007) 61 (2) pp. 372-383 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

GHENT UNIV LAB MICROBIAL ECOLOGY & TECHNOL GHENT BELGIUM

H20962 XANTHOHUMOLS, DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS, FROM HUMULUS LUPULUS.

TABATA,N: ITO,M: TOMODA,H: OMURA,S:

PHYTOCHEMISTRY (1997) 46 (4) pp. 683-687 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

KITASATO INST RES CENT BIOL FUNCTION TOKYO 108 JAPAN

H31111 INHIBITORS OF NITRIC OXIDE PRODUCTION FROM HOPS (HUMULUS LUPULUS L.).

ZHAO,F: NOZAWA,H: DAIKONNYA,A: KONDO,K: KITANAKA,S:

BIOL PHARM BULL (2003) 26 (1) pp. 61-65 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

KIRIN BREWERY CO LTD CENTRAL LAB KEV TECHNOLOGY KANAGAWA 2360004 JAPAN

H32723 PRENYLFLAVONOIDS AND PHLOROGLUCINOL DERIVATIVES FROM HOPS (HUMULUS LUPULUS).

ZHAO,F: WATANABE,Y: NOZAWA,H: DAIKONNYA,A: KONDO,K: KITANAKA,S:

J NAT PROD (2005) 68 (1) pp. 43-49 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

KIRIN BREWERY CO LTD CENT LAB KEY TECHNOL KANAGAWA 2360004 JAPAN

L03979 ANTIPROLIFERATIVE AND CYTOTOXIC EFFECTS OF PRENYLATED FLAVONOIDS FROM HOPS (HUMULUS LUPULUS) IN HUMAN CANCER CELL LINES.

MIRANDA,CL: STEVENS,JF: HELMRICH,A: HENDERSON,MC: RODRIGUEZ,RJ: YANG,YH: DEINZER,ML: BARNES,DW: BUHLER,DR:

FOOD CHEM TOXICOL (1999) 37 (4) pp. 271-285 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIV DEPT ENVIRON MOL TOXICOL COLL PHARM CORVALLIS OR 97331 USA

LITERATURE CITED

L04448 IDENTIFICATION OF A POTENT PHYTOESTROGEN IN HOPS (HUMULUS LUPULUS L.) AND BEER.

MILLIGAN,SR: KALITA,JC: HEYERICK,A: RONG,H: DE COOMAN,L: DE KEUKELEIRE,D:

J CLIN ENDOCRINOL METAB (1999) 83 (6) pp. 2249-2252 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

KING'S COLL PHYSIOL DIV SCH BIOMED SCI LONDON ENGLAND

L08929 FATE OF XANTHOHUMOL AND RELATED PRENYLFLAVONOIDS FROM HOPS TO BEER.

STEVENS,JF: TAYLOR,AW: CLAWSON,JE: DEINZER,ML:

J AGR FOOD CHEM (1999) 47 (6) pp. 2421-2428 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIV DEPT CHEM CORVALLIS OR 97331 USA

L10217 ANTIOXIDANT AND PROOXIDANT ACTIONS OF PRENYLATED AND NONPRENYLATED CHALCONES AND FLAVANONES IN VITRO.

MIRANDA,CL: STEVENS,JF: IVANOV,V: MC CALL,M: FREI,B: DEINZER,ML: BUHLER,DR:

J AGR FOOD CHEM (2000) 48 pp. 3876-3884 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIV DEPT CHEM CORVALLIS OR USA

L10219 IN VITRO INHIBITION OF HUMAN P450 ENZYMES BY PRENYLATED FLAVONOIDS FROM HOPS, HUMULUS LUPULUS.

HENDERSON,MC: MIRANDA,CL: STEVENS,JF: DEINZER,ML: BUHLER,DR:

XENOBIOTICA (2000) 30 (3) pp. 235-251 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIV DEP ENVIRONMENTAL MOL TOXICOL CHEM CORVALLSI OR 97331 USA

L14681 THE OESTROGENIC ACTIVITY OF HOPS (HUMULUS LUPULUS L.) REVISITED.

KEUKELEIRE,D: MILLIGAN,D: COOMAN,D: HEYERICK,L:

PHARM PHARMACOL LETT (1997) 7 (2/3) pp. 83-86 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV GENT FAC PHARM SCIENCES LAB PHARMACO PHYTOCHEM GENT BELGIUM

L15429 INFLUENCE OF PRENYLATED AND NON-PRENYLATED FLAVONOIDS ON LIVER MICROSOMAL LIPID PEROXIDATION AND OXIDATIVE INJURY IN RAT HEPATOCYTES.

RODRIGUEZ,RJ: MIRANDA,CL: STEVENS,JF: DEINZER,ML: BUHLER,DR:

FOOD CHEM TOXICOL (2001) 39 (5) pp. 437-445 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIV DEPT PHARMACEUTICAL SCI CORVALLIS OR USA

LITERATURE CITED

L19788 APOPTOSIS AND CYTOTOXICITY TO HL-60 BY TWO BONE RESORPTION INHIBITORS, HUMULONE AND XANTHOHUMOL.

TOBE,H:

GAKUJUTSU KIYO KOCHI KOGYO KOTO SENMON GAKKO (2000) 45 pp. 39-44 INFORMATION CODED FROM AN ABSTRACT. * CHEMICAL ABSTRACTS 134 51165 A

KOCHI NATION COLL TECHNOL DEPT MATERI SCI ENGINEE JAPAN

L25890 IDENTIFICATION AND BIOLOGICAL ACTIVITY OF MICROBIAL METABOLITES OF XANTHOHUMOL.

HERATH,W: FERREIRA,D: KHAN,SI: KHAN,IA:

CHEM PHARM BULL (2003) 51 (11) pp. 1237-1240 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV MISSISSIPPI NAT CENT DEV NAT PROD RES INST PHARM SCI UNIVERSITY MS 38677 USA

L25902 ANTIVIRAL ACTIVITY OF HOP CONSTITUENTS AGAINST A SERIES OF DNA AND RNA VIRUSES.

BUCKWOLD,VE: WILSON,RJH: NALCA,A: BEER,BB: VOSS,TG: TURPIN,JA: BUCKHEIT III,RW: WEI,J: WENZEL-MATHERS,M: WALTON,EM: SMITH,RJ: PALLANSCH,M: WARD,P: WELLS,J: CHUVALA,L: SLOANE,S: PAULMAN,R: RUSSELL,J: HARTMAN,T: PTAK,R:

ANTIVIRAL RES (2004) 61 (1) pp. 57-62 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

SOUTHERN RES INST INFECT DIS RES DEPT FREDERICK MD 21701 USA

L26307 INHIBITION OF STREPTOCOCCUS MUTANS AND OTHER ORAL STREPTOCOCCI BY HOP (HUMULUS LUPULUS L.) CONSTITUENTS.

BHATTACHARYA,S: VIRANI,S: ZAVRO,M: HAAS,GJ:

ECON BOT (2003) 57 (1) pp. 118-125 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

FAIRLEIGH DICKINSON UNIV SCH NAT SCI TEANECK NJ 07666 USA

L26905 IN VITRO PHASE II METABOLISM OF XANTHOHUMOL BY HUMAN UDP-GLUCURONOSYLTRANSFERASES AND SULFOTRANSFERASES.

RUEFER,CE: GERHAUSER,C: FRANK,N: BECKER,H: KULLING,SE:

MOL NUTR FOOD RES (2005) 49 pp. 851-856 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

FED RES CEN NUTR FOOD INST NUTR PHYSIOL KARLSRUHE GERMANY

L26906 XANTHOHUMOL INDUCES APOPTOSIS IN CULTURED 40-16 HUMAN COLON CANCER CELLS BY ACTIVATION OF THE DEATH RECEPTOR- AND MITOCHONDRIAL PATHWAY.

PAN,L: BECKER,H: GERHAUSER,C:

MOL NUTR FOOD RES (2005) 49 pp. 837-843 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

GERMAN CAN RES CEN DIV TOX CANCER RISK FACTORS HEIDELBERG GERMANY

L26907 XANTHOHUMOL KILLS B-CHRONIC LYMPHOCYTIC LEUKEMIA CELLS BY AN APOPTOTIC MECHANISM.
LUST,S: VANHOECKE,B: JANSSENS,A: PHILIPPE,J: BRACKE,M: OFFNER,F:
MOL NUTR FOOD RES (2005) 49 pp. 844-850 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
GHENT UNIV HOSP DEPT HEMATOL GENT BELGIUM

L26908 XANTHOHUMOL DOES NOT AFFECT THE COMPOSITION OF RAT INTESTINAL MICROBIOTA.
HANSKE,L: HUSSONG,R: GERHAUSER,C: BLAUT,M: BRAUNE,A:
MOL NUTR FOOD RES (2005) 49 pp. 868-873 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
GERMAN INST HUM NUTR POTSDAM DEPT GESTROINTEST MICROBIOL NUTHETAL GERMANY

L26909 A SAFETY STUDY OF ORAL XANTHOHUMOL ADMINSTRATION AND ITS INFLUENCE ON FERTILITY IN SPRAGUE DAWLEY RATS.
HUSSONG,R: FRANK,N: ITTRICH,C: OWEN,R: BECKER,H: GERHAUSER,C:
MOL NUTR FOOD RES (2005) 49 pp. 861-867 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
DEUTSCHES KREBSCHUNGSZENTRUM DIV TOXICOL CAN RISK FACTORS HEIDELBERG GERMANY

L27032 XANTHOHUMOL METABOLITES IN FAECES OF RATS.
NOOKANDEH,A: FRANK,N: STEINER,F: ELLINGER,R: SCHNEIDER,B: GERHAUSER,C: BECKER,H:
PHYTOCHEMISTRY (2004) 65 (5) pp. 561-570 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
UNIV SAARLANDS PHARMAKOG & ANAL PHYTOCHEM SAARBRUCKEN D-6600 GERMANY

L27089 XANTHOHUMOL STIMULATES IODIDE UPTAKE IN RAT THYROID-DERIVED FRTL-5 CELLS.
RADOVIC,B: SCHUMUTZLER,C: KOHRIE,J:
MOL NUTR FOOD RES (2005) 49 pp. 832-836 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
CHARITE UNIV BERLIN INST EXPER ENDOKRINOL FORSCHUNGSZENTRUM ENFORCE BERLIN D-10117 GERMANY

L27365 IN VITRO GLUCURONIDATION OF XANTHOHUMOL, A FLAVONOID IN HOPS AND BEER, BY RAT AND HUMAN LIVER MICROSOMES
YILMAZER,M: STEVENS,JF: BUHLER,DR:
FEBS LETT (2001) 491 pp. 252-256 SOURCE WAS AN ORIGINAL RESEARCH PAPER.
OREGON STATE UNIV DEPT ENVIRONMENTAL MOLECULAR TOXICOLOGY CORVALLIS OR 97331 USA

L27366 INFLUENCE OF PRENYLATED FLAVONOIDS ON LIVER MICROSOMAL LIPID PEROXIDATION AND OXIDATIVE INJURY IN RAT HEPATOCYTES

RODRIGUEZ,RF: MIRANDA,CL: STEVENS,JF: DEINZER,ML: BUHLER,DR:

FOOD CHEM TOXICOL (2001) 39 pp. 437-445 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIV DEPT PHARM SCI CORVALLIS OR USA

L27367 IN VITRO BIOTRANSFORMATION OF XANTHOHUMOL, A FLAVONOID FROM HOPS (HUMULUS LUPULUS), BY RAT LIVER MICROSOMES.

YILMAZER,M: STEVENS,JF: DEINZER,ML: BUHLER,DR:

DRUG METAB DISPOS (2001) 29 (3) pp. 223-231 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIV DEPT ENVIRON MOL TOXICOL CORVALLIS OR USA

L27368 INHIBITION OF PEROXYNITRITE-MEDIATED LDL OXIDATION BY PRENYLATED FLAVONOIDS: THE A,B-UNSATURATED KETO FUNCTIONALITY OF 2'-HYDROXYCHALCONES AS A NOVEL ANTIOXIDANT PHARMACOPHORE.

STEVENS,JF: MIRANDA,CL: FREI,B: BUHLER,D:

CHEM. RES. TOXICOL (2003) 16 pp. 1277-1286 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIV DEPT CHEM CORVALLIS OREGON 97331-7301 USA

L27369 PRENYLATED CHALCONES AND FLAVANONES AS INDUCERS OF QUINONE REDUCTASE IN MOUSE HEPA 1C1C7 CELLS.

MIRANDA,CL: APONSO,GLM: STEVENS,JF: DEINZER,ML: BUHLER,DR:

CANCER LETT (2000) 149 pp. 21-29 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIV DEPT ENVIRON MOL TOXICOLOGY CORVALLIS OREGON 97331 USA

L27370 THE ENDOCRINE ACTIVITIES OF 8-PRENYLNARINGENIN AND RELATED HOP (HUMULUS LUPULUS L.) FLAVONOIDS.

MILLIGAN,SR: KALITA,JC: POCOCK,V: VAN DE KAUTER,V: STEVENS,JF: DEINZER,ML: RONG,H: DE KEUKELEIRE,D:

J CLIN ENDOCRINOL METAB (2000) 85 (12) pp. 4912-4915 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIV DEPT CHEM CORVALLIS OREGON 97331 USA

L27371 PRENYLFLAVONOIDS FROM HOPS INHIBIT THE METABOLIC ACTIVATION OF THE CARCINOGENIC HETEROCYCLIC AMINE 2-AMINO-3-METHYLIMIDAZO[4,5-F]QUINOLINE, MEDIATED BY CDNA-EXPRESSED HUMAN CYP1A2.

MIRANDA,CL: YANG,YH,: HENDERSON,MC: STEVENS,JF: SANTANA-RIOS,G: DEINZER,ML: BUHLER,DR:

DRUG METAB DISPOS (2000) 28 (11) pp. 1297-1302 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIV DEPT CHEM CORVALLIS OREGON 97331-7301 USA

LITERATURE CITED

L28323 ACTIVATION OF PROESTROGENS FROM HOPS (HUMULUS LUPULUS L.) BY INTESTINAL MICROBIOTA; CONVERSION OF ISOXANTHOHUMOL INTO 8-PRENYLNARINGENIN.

POSSEMIERS,S: HEYERICK,A: ROBBINS,V: DE KEUKELEIRE,D: VERSTRAETE,W:

J AGR FOOD CHEM (2005) 53 pp. 6281-6288 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

GENT UNIV LAB MICROBIAL ECOLOGY TECH FAC BIOSCI ENG GENT B-9000 BELGIUM

L29205 METABOLISM OF XANTHOHUMOL AND ISOXANTHOHUMOL,PRENYLATED FLAVONOIDS FROM HOPS (HUMULUS LUPULUS L.), BY HUMAN LIVER MICROSOME.

NIKOLIC,D: LI,YM: CHADWICK,LR: PAULI,GF: VAN BREEMEN,RB:

J MASS SPECTROM (2005) 40 pp. 289-299 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV ILL CHGO DEPT MED CHEM PHARMACOG COLL PHARM CHICAGO IL 60612-7231 USA

L29296 XANTHOHUMOL ISOLATED FROM HUMULUS LUPULUS INHIBITS MENADIONE-INDUCED DNA DAMAGE THROUGH INDUCTION OF QUINONE REDUCTASE

DIETZ,BR: KANG,YH: LIU,GW: EGGLER,AL: YAO,P: CHADWICK,LR: PAULI,GF: FARNSWORTH,NR: MESECAR,AD: VAN BREEMEN,RB: BOLTON,JL:

CHEM RES TOXICOL (2005) 18 (8) pp. 1296-1305 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

COLLEGE OF PHARMACY, UNIVERSITY OF ILLINOIS AT CHICAGO DEPARTMENT OF MEDICINAL CHEMISTRY AND PHARMACOGNOSY UIC/NIH CENTER FOR BOTANICAL AND DIETARY SUPPLEMENTS CHICAGO ILLINOIS 60612 USA

L29422 XANTHOHUMOL, A PRENYLFLAVONOID DERIVED FROM HOPS INDUCES APOPTOSIS AND INHIBITS NF-KAPPA-B ACTIVATION IN PROSTATE EPITHELIAL CELLS

COLGATE,EC: MIRANDA,CL: STEVENS,JF: BRAY,TM: HO,E:

CANCER LETT (2007) 246 (2007) pp. 201-209 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

OREGON STATE UNIVERSITY DEPARTMENT OF NUTRITION AND EXERCISE SCIENCES CORVALLIS OREGON USA

L30162 MODULATION OF BREAST CANCER CELL SURVIVAL BY AROMATASE INHIBITION HOP (HUMULUS IUPULUS L.) FLAVONOIDS

MONTEIRO,R: FARIA,A: AZEVEDO,I: CALHAU,C:

J STEROID BIOCHEM MOL BIOL (2007) 105 pp. 124-130 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV PORTO DEPT BIOCHEM FACULTY MEDICINE PORTO 4200-319 PORTUGAL

L30184 SYNTHESIS OF DEMETHYLXANTHOHUMOL, A NEW POTENT APOPTOSIS-INDUCING AGENT FROM HOPS.

DILLER,RA: RIEPL,HM: FRIAS,C: HENZE,G: PROKOP,A:

CHEMISTRY & BIODIVERSITY (2005) 2 pp. 1331-1337 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

TECHNICAL UNIV MUNICH INST TECHNOL BIOGENIC RES MUNICH D-94315 GERMANY

LITERATURE CITED

L30185 IN VITRO ANTIPLASMODIAL ACTIVITY OF PRENYLATED CHALCONE DERIVATIVES OF HOPS (HUMULUS LUPULUS) AND THEIR INTRACTION WITH HAEMIN.

FROLICH,S: SCHUBERT.C: BIENZLE,U: JENETT-SIEMS,K:

J ANTIMICROB CHEMOTHER (2005) 55 pp. 883-887 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

FREIE UNIV BERLIN INST PHARM BERLIN D-141195 GERMANY

L30188 XANTHOHUMOL, A NOVEL ANTI-HIV-1 AGENT PURIFIED FROM HOPS HUMULUS LUPULUS.

WANG,Q: DING,ZH: LIU,JK: ZHRNG,YT:

ANTIVIRAL RES (2004) 64 pp. 189-194 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

CHIN ACAD SCI LAB MOLE IMMUNOPHARMACOL KUNMING INST ZOOLOGY KUNMING 650223 CHINA

L30191 BINDING OF THE HOP (HUMULUS LUPULUS L.) CHALCONE XANTHOHUMOL TO CYTOSOLIC PROTEINS IN CACO-2 INTESTINAL EPITHELIAL CELLS.

PANG,Y: NIKOLIC,D: ZHU,DW: CHADWICK,LR: PAULI,GF: FARNSWORTH,NR: VAN BREEMEN,RB:

MOL NUT FOOD RES (2007) 51 pp. 872-879 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIVERSITY OF ILLINOIS AT cHICAGO DEPT MED CHEM & PHARMACOGNOSY COLLEGE OF PHARMACY CHICAGO IL 60612 USA

L30193 XANTHOHUMOL ISOLATED FROM HUMULUS LUPULUS INHIBITS MENADIONE-INDUCED DNA DAMAGE THROUGH INDUCTION OF QUINONE REDUCTASE

DIETZ,BM; KANG,YH; LIU, GW; EGGLER, AL; YAO,P; CHADWICK,LR; PAULI,GF; FARNSWORTH,NR; MESECAR,AD; VAN BREEMEN,RB; BOLTON,JL

CHEM RES TOXICOL (2005) 18 (8) pp. 1296-1305 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV ILLINOIS CHICAGO DEPT MED CHEM PHARMACOGNOSY COLL PHARM CHICAGO IL USA

L30195 EFFECT OF HOP (HUMULUS LUPULUS L.) FLAVONOIDS ON AROMATASE (ESTROGEN SYNTHASE) ACTIVITY.

MONTEIRO,R: BECKER,H: AZEVEDO,I: CALHAU,C:

J AGR FOOD CHEM (2006) 54 pp. 2938-2943 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV PORTO DEPT BIOCHEM FAC MED PORTUGAL

L30197 ANTICOCCIDIAL EFFECTS OF XANTHOHUMOL.

ALLEN,PC:

AVIAN DISEASES (2007) 51 pp. 21-26 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

ANIMAL PARASITIC DISEASES LAB U.S DEPT AGRI-AGRI RES SERVICE BELTSVILLE MD 20705 USA

LITERATURE CITED

L30198 MECHANISMS OF THE ANTIANGIOGENIC ACTIVITY BY THE HOP FLANONOID XANTHOHUMOL: NF-KB AND AKT AS TARGETS.

ALBINI,A: DELL-EVA,R: VENE,R: FERRARI,N: BUHLER,DR: NOONAN,DM: FASSINA,G:

FASEB J EXPRESS ARTICLE 10.1096/FJ.05.5128.FJE (2005) 2005 pp. 1-21 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

MOLE ONCOL LAB ISTITUO NAZIONALE PER LA RICERCA SUL CANCRO GENOA ITALY

L30199 ANTIINVASIVE EFFECT OF XANTHOHUMOL, A PRENYLATED CHALCONE PRESENT IN HOPS (HUMULUS LUPULUS L.) AND BEER.

VANHOECKE,B: DERYCKE,L: VAN MARCK,V: DEPYPERE,H: DE KEUKELEIRE,D: BRACKE,M:

INT J CANCER (2005) 117 pp. 889-895 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

GHENT UNIV HOSP DEPT GYNECOLOGY GHENT B-9000 BELGIUM

L30201 EFFECT OF XANTHOHUMOL AND ISOANTHOHUMOL ON 3T3-L1 CELL APOPTOSIS AND ADIPOGENESIS.

YANG,JY: DELLA-FERA,MA: RAYALAM,S: BAILE,CA:

APOPTOSIS (2007) 12 pp. 1953-1963 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV GEORGIA DEPT ANIMAL DAIRY SCI ATHENS GA 30602-2771 USA

L30215 IDENTIFICATION OF HUMAN HEPATIC CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF 8-PRENYLNARINGENIN AND ISOXANTHOHUMOL FROM HOPS (HUMULUS LUPULUS L.)

GUO,J; NIKOLIC,D; CHADWICK,LR; PAULI,GF; VAN BREEMEN,RB

DRUG METABOL DISPOSIT (2006) 34 (7) pp. 1152-1159 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV ILLINOIS CHICAGO DEPT MED CHEM PHARMACOGNOSY COLL PHARM CHIGAGO IL 60612 USA

L30218 SCREENING METHOD FOR THE DISCOVERY OF POTENTIAL CANCER CHEMOPREVENTION AGENTS BASED ON MASS SPECTROMETRIC DETECTION OF ALKYLATED KEAP1

LIU,G; EGGLER,A; DIETZ,B; MESECAR,A; BOLTON,JA; PEZZUTO,JM; VAN BREEMEN,RB

ANAL CHEM (2005) 77 (19) pp. 6407-6414 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV ILLINOIS CHICAGO DEPT MED CHEM PHARMACOGNOSY COLL PHARM CHICAGO IL 60612 USA

L30228 XANTHOHUMOL, THE CHALCONE FROM BEER HOPS (HUMULUS LUPULUS L.), IS THE LIGAND FOR FARNESOID X RECEPTOR AND AMELIORATES LIPID AND GLUCOSE METABOLISM IN KK-AY MICE

NOZAWA,H

BIOCHEM BIOPHYS RES COMMUN (2005) 336 (3) pp. 754-761 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

KIRIN BREWERY CO. LTD. R & D LABORATORY FUNCTIONAL FOOD DIVISION GUNMA 370-1295 JAPAN

LITERATURE CITED

L30229 REGULATION OF OSTEOBLASTIC PHENOTYPE AND GENE EXPRESSION BY HOP-DERIVED PHYTOESTROGENS

EFFENBERGER,KE; JOHNSEN,SA; MONROE,DG; SPELSBERG,TC; WESTENDORF,JJ

J STEROID BIOCHEM MOL BIOL (2005) 96 (5) pp. 387-399 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV HAMBURG INSTITUTE FOR EXPERIMENTAL AND CLINICAL PHARMACOLOGY AND TOXICOLOGY UNIV HOSPITAL EPPENDORF HAMBURG 22527 GERMANY

L30230 INFLUENCE OF XANTHOHUMOL ON THE BINDING BEHAVIOR OF GABA-A RECEPTORS AND THEIR LATERAL MOTILITY AT HIPPOCAMPAL NEURONS

MEISSNER,O; HAEBERLEIN,H:

PLANTA MED (2006) 72 (7) pp. 656-658 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV MARBURG DEPT PHARM BIOLOGY MARBURG GERMANY

L30253 TREATMENT OF PC-3 AND DU145 PROSTATE CANCER CELLS BY PRENYLFLAVONOIDS FROM HOP (HUMULUS LUPULUS L.) INDUCES A CASPASE -INDEPENDENT FORM OF CELL DEATH

DELMULLE,L: VANDEN BERGHE,T: DE KEUKELEIRE,D: VANDENABEELE,P

PHYTOTHER RES 22 (2) pp. 197-203 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV GHENT FACULTY OF PHARMACEUTICAL SCIENCES LABORATORY OF PHARMACOGNOSY AND PHYTOCHEMISTRY GHENT B-9000 BELGIUM

L30258 CANCER CHEMOPREVENTIVE ACTIVITY OF XANTHOHUMOL, A NATURAL PRODUCT DERIVED FROM HOP

GERHAUSER,C: ALT,A: HEISS,E: GAMAL-ELDEEN,A: KLIMO,K: KNAUFT,J: NEUMANN,I: SHERF,HR: FRANK,N: BARTSCH,H: BECKER,H

MOLECULAR CANCER THERAPEUTICS (2002) 1 (11) pp. 959-969 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

DEUTSCHES KREBSFORSCHUNGZENTRUM HEIDELBERG GERMANY

L30335 PROTECTIVE EFFECTS OF XANTHOHUMOL AGAINST THE GENOTOXICITY OF BENZO(A)PYRENE (BAP), 2-AMINO-3-METHYLIMIDAZO[4,5-F] QUINOLINE (IQ) AND TERT-BUTYL HYDROPEROXIDE (T-BOOH) IN HEP G2 HUMAN HEPATOMA CELLS

PLAZAR,J: ZEGURA,B: LAH,TT: FILIPIC,M:

MUTAT RES (2007) 632 pp. 1-8 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

NAT INST BIOL LJUBLJANA 1000 SLOVENIA

L30466 ANTI-PROLIFERATIVE PROPERTIES OF PHENYLATED FLAVONOIDS FROM HOPS (HUMULUS LUPULUS L.) IN HUMAN PROSTATE CANCER CELL LINES

DELMULLE,L: BELLAHCENE,A: DHOOGE,W: COMHAIRE,F: ROELENS,F: HUVAERE,K: HEYERICK,A: CASTRONOVO,V: DEKEUKELEIRE,D

PHYTOMEDICINE (2006) 13 pp. 732-734 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

GHENT UNIV FAC PHARM SCI GHENT B-9000 BELGIUM

LITERATURE CITED

L30574 IDENTIFICATION OF HUMAN HEPATIC CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF 8-PRENYLNARINGENIN AND ISOXANTHOHUMOL FROM HOPS (HUMULUS LUPULUS L.).

GUO,J: NIKOLIC,D: CHADWICK,LR: PAULI,GF: VAN BREEMEN, BR:

DRUG METABOLISM DISPOSITION (2006) 34 (7) pp. 1152-1159 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV ILL CHICAGO DEPT MED CHEM PHARMACOL COLL PHARMACY CHICAGO ILLINOIS 60612 USA

L30576 INFLUENCE OF XANTHOHUMOL ON THE BINDING BEHAVIOR OF GABAA RECEPTORS AND THEIR LAATERAL MOBILITY AT HIPPOCAMPAL NEURONS.

MEISSNER,O: HABERLEIN,H:

PLANTA MED (2006) 72 pp. 656-658 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV MARBURG DEPT PHARMACEUT BIOL MARBURG GERMANY

L30577 ANTIGENOTOXIC EFFECT OF XANTHOHUMOL IN RAT LIVER SLICES.

PLAZAR,J: FILIPIC,M: GROOTHUIS,GMM:

TOXICOLOGY (2008) 22 (2) pp. 318-327 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV GRONINGEN DEPT PHARMACOKINETICS DRUG DELIVERY UNIV CENT PHARMACY GRONINGEN NETHERLANDS

L30636 ANTIMUTAGENICITY OF HOPS (HUMULUS LUPULUS L.): BIOASSAY-DIRECTED FRACTIONATION AND ISOLATION OF XANTHOHUMOL

KAC,J: PLAZAR,J: MLINARIC,A: ZEGURA,B: LAH,TT: FILIPIC,M

PHYTOMEDICINE (2008) 15 (3) pp. 216-220 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

UNIV LJUBLJANA DEPT PHARMACEUTICAL BIOL FAC PHARMACY LJUBLJANA SLOVENIA

M12709 INHIBITION OF ADENOSINE 3',5'-CYCLIC MONOPHOSPHATE PHOSPHODIESTERASE BY COMPONENTS OF SOPHORA FLAVESCENS AITON.

OHMOTO,T: AIKAWA,R: NIKAIDO,T: SANKAWA,U: WU,LJ: UENO,A: FUKUSHIMA,S:

CHEM PHARM BULL (1986) 34 (5) pp. 2094-2099 SOURCE WAS AN ORIGINAL RESEARCH PAPER.

TOHO UNIV SCH PHARMACEUT SCI CHIBA 274 JAPAN